KOD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kodiak Sciences Inc. (KOD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong positive momentum in technical indicators, favorable analyst ratings, and significant institutional interest. Despite financial losses, the company's R&D investments and potential in the anti-VEGF market position it well for future growth. The absence of Intellectia Proprietary Trading Signals does not detract from the long-term potential.
The technical indicators for KOD are bullish. The MACD histogram is positive and expanding, suggesting upward momentum. The RSI is neutral at 70.411, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm a bullish trend. The stock is trading above key pivot levels, with resistance at R1: 28.056 and R2: 29.861, indicating room for further upside.
Analysts have raised price targets and maintained Buy ratings, citing potential catalysts such as Phase 3 data for key drugs.
Institutional investors like Baker Bros. Advisors have significantly increased their stake, reflecting confidence in the company's prospects.
The company is targeting the $15 billion anti-VEGF market, which could lead to significant revenue growth if Phase 3 data validates its platform.
The company reported a net loss of $61.5 million in Q3 2025, with no revenue growth.
The stock has a mixed short-term trend, with a 50% chance of declining 3.47% over the next month.
In Q3 2025, Kodiak Sciences reported no revenue growth, with revenue remaining at $0. However, net income improved by 39.85% YoY to -$61.5 million, and EPS improved by 38.10% YoY to -1.16. The company continues to invest heavily in R&D, spending $50.5 million in the quarter, with cash reserves of $72 million.
Analysts are bullish on KOD. H.C. Wainwright raised the price target to $38 from $26, citing increased probability of success for key drugs. UBS initiated coverage with a Buy rating and a $50 price target, highlighting the company's strong pipeline and upcoming catalysts.
